🔴 Telix Pharmaceuticals is trading 4.1% down in pre-market — possible profit-taking after Pixclara approval

Telix Pharmaceuticals is trading 4.13% down at $12.30 in pre-market, possibly reflecting profit-taking after its approval-driven rally.

• It rose 8.91% to $12.83 on September 15, 2026.
• The latest major catalyst is FDA approval of Pixclara on September 14, 2026, the first FDA-approved FET-PET imaging drug for glioma.
• No fresh negative company announcement was identified; broader futures are modestly higher, so market weakness does not clearly explain the decline.